Results 121 to 130 of about 51,890 (248)

Patients' Experiences With Multiple Myeloma: A Meta-Aggregation of Qualitative Studies.

, 2017
To access publisher's full text version of this article click on the hyperlink belowTo systematically review qualitative evidence regarding patients' experiences of living with multiple myeloma.
Gunnarsdóttir, Sigríður, Björnsdóttir, Kristín, Hauksdóttir, Brynja, Klinke, Marianne E   +3 more
core   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Role of minimal residual disease assessment in multiple myeloma

Haematologica
Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells. MM is a heterogeneous disease, featured by various molecular subtypes with different outcomes. With the advent of very efficient therapies including
Raphael Szalat, Kenneth Anderson, Nikhil Munshi   +2 more
doaj   +1 more source

Targeting the mTOR and TRAIL Pathways in Multiple Myeloma. Resumen de tesis

, 2012
Extracto de tesis.[ES] Aunque hay varios estudios que destacan la activación de la vía PI3K/Akt en mieloma, hay menos información sobre el estado y el papel de la vía mTOR.
Chen, Xi
core  

Discharge Remote Monitoring Systems for Glycemic Management After Hospital Discharge

Chronic Diseases and Translational Medicine, EarlyView.
Heat map of median number of telehealth interactions by subgroup and theme. Major themes identified included intervention after remote monitoring alerts (e.g., “Team reached out to participant and instructed participant to treat hypo.”), insulin dose adjustments (e.g., “Participant reported that prednisone dose is increasing … Called to discuss insulin
Nirali Shah, Camilla Levister, Riana Jumamil, Carol Levy, Margaret Crawford, Christian Hicks, Selassie Ogyaadu, Aslihan Ipek, Abigail Tamru, Madeleine Rouviere, Leah Kaplan, Ying Xu, Harsimran Singh, Daniel Cherñavvsky, Grenye O'Malley   +14 more
wiley   +1 more source

t(11;14) multiple myeloma patient: minimal residual disease after 10 years of follow-up - a case report

Haematologica
Not available.
Sarah Decheiver, Anais Schavgoulidze, Sabrina Maheo, Pierre-Adrien Vion, Olivier Lucidarme, Jill Corre, Laurent Garderet   +6 more
doaj   +1 more source

Bortezomib in the management of multiple myeloma

, 2009
Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, Robert Schlossman, Dharminder Chauhan, Nikhil Munshi, Irene Ghobrial, Nicole Carreau, Kenneth C Anderson, Paul G RichardsonDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston ...
Teru Hideshima, et al, Jacob P Laubach, Constantine S Mitsiades   +3 more
core  

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

Clinical Pharmacology &Therapeutics, EarlyView.
ISB 2001 is a trispecific antibody that binds to two tumor‐associated antigens (TAA), CD38 and BCMA, and crosslinks to CD3 on T cells resulting in T cell‐mediated cytotoxicity of tumor cells expressing these TAAs. ISB 2001 is currently being tested in relapsed and/or refractory multiple myeloma (RRMM) patients in the first‐in‐human (FIH) TRIgnite‐1 ...
Vinu Chandralayam Ayyappa Menon, Tomomi Matsuura, Beata Holkova, Girish S. Gudi, Adam Drake, Maria Pihlgren, Piet H. van der Graaf, Sunitha GN, Andrew Garton, Mario Perro, Cyril Konto, Lida Pacaud   +11 more
wiley   +1 more source

Dissecting immunophenotypic diversity in multiple myeloma via mass cytometry: a call for harmonized gating strategies

Frontiers in Immunology
Plasma cell disorders present challenges in phenotypic determination, as they range from monoclonality of plasma cells to multiple myeloma and plasma cell leukemia.
Mahmoud Singer, Milad Moloudizargari, Milad Moloudizargari, James Sanchez, Flavia Pichiorri, Flavia Pichiorri   +5 more
doaj   +1 more source

The role of mitochondrial DNA in the tumor biology of glioblastoma multiforme and multiple myeloma [PDF]

Cancer cells preferentially metabolise glucose via aerobic glycolysis (the Warburg effect), which is less energy efficient in teens of ATP production compared to oxidative phosphorylation (OXPHOS).
Yeung, Ka Yu
core